Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving virus or bacteriophage
Reexamination Certificate
2006-06-27
2006-06-27
Parkin, Jeffrey S. (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving virus or bacteriophage
C424S188100, C424S208100
Reexamination Certificate
active
07067246
ABSTRACT:
The serum levels of anti-tat antibodies, tat protein, and p24 protein are predictive of disease progression in HIV infected individuals and serve as prognostic markers. The present invention relates to a method for determining the prognosis of an HIV infected individual by measuring serum levels of one or more of these prognostic markers. In addition, a method for monitoring whether an HIV infected individual is in need of immunization with a tat vaccine and a method for monitoring the efficacy of immunization with a tat vaccine are also disclosed.
REFERENCES:
patent: 5108891 (1992-04-01), Croxson
patent: 195 14 089 (1996-10-01), None
Reiss, P., et al., 1991, “Contribution of anitbody response to recombinant HIV-1 gene-encoded products nef, rev, tat, and protease in predicting development of AIDS in HIV-1 infected individuals.”, J. Acquir. Immune Defic. Syndr. 4:165-172.
Franchini, G., et al., 1987, “Spectrum of natural antibodies against five HTLV-III antigens in infected individuals: correlation of antibody prevalence with clinical status.”, Blood 69(2):437-441.
Krone, W. J. A., et al., 1988, “Natural antibodies to HIV-tat epitopes and expression of HIV-1 genes in vivo.”, J. Med. Virol. 26:261-270.
Donovan, R. M., et al., 1996, “Changes in virus load markers during AIDS-associated opportunistic diseases in human immunodeficiency virus-infected persons.”, J. Infect. Dis. 174:401-3.
Pedersen, C., et al., 1992, “The effect of treatment with zidovudine with or without acyclovir on HIV p24 antigenaemia in patients with AIDS or AIDS-related complex.”, AIDS 6:821-825.
Molina, J.-M., et al., 1994, “Quantification of HIV-1 virus load under zidovudine therapy in patients with symptomatic HIV infection: relation to disease progression.”, AIDS 8:27-33.
Lafeuillade, A., et al., 1994, “Correlation between surrogate markers, viral load, and disease progression in HIV-1 infection.”, J. Acquir. Immune Defic. Syndr. 7:1028-1033.
Letvin, N., 1998, “Progress in the development of an HIV-1 vaccine.”, Science 280:1875-1880.
Johnston, M. I., 2000, “The role of nonhuman primate models in AIDS vaccine development.”, Mol. Med. Today 6:267-270.
Burton, D. R., and J. P. Moore, 1998, “Why do we not have an HIV vaccine and how can we make one?”, Nature Med. Vaccine Suppl. 4(5):495-498.
Lee, T.-H., 1997, “Acquired immunodeficiency disease vaccines: design and development.”, inAIDS: Biology, Diagnosis, Treatment and Prevention, fourth edition, DeVita, V. T., et al., eds., Lippincott-Raven Publishers, pp. 605-616.
Rodman, T. C., et al., 1992, “Human immunodeficiency virus (HIV) Tat-reactive antibodies present in normal HIV-negative sera and depleted in HIV-positive sera. Identification of the epitope”, J. Exp. Med. 175:1247-1253.
Zagury et al., “Antibodies to the HIV-1 Tat Protein Correlated With Nonprogression to AIDS: A Rationale for the Use of Tat Toxoid as an HIV-1 Vaccine,” J. of Human Virology, May/Jun. 1998., vol. 1, No. 4, pp. 282-292.
Rodman et al., “Epitopes for Natural Antibodies of Human Immunodeficiency Virus (HIV)-negative(normal) and HIV-positive sera are coincident with two key functional sequences of HIV tat Protein,” Proc. of Nat. Academy of Sciences, USA, Aug. 1993, vol. 90, pp. 7719-7723.
Rodman et al., “Natural Antibodies. Early hose defense against HIV? ,” International Conf. on AIDS, 1992, vol. 8, No. 2, pp. A74 (abstract No. POA 2429).
Re et al., “Antibody Against Human Immunodeficiency Virus type 1 (HIV-1). Tat Protein may have influenced the progression of AIDS in HIV-1 infected hemophiliac patients,” Clinical and Diagnostic Laboratory Immunology, Mar. 1996, vol. 3, No. 2, pp. 230-232.
Re et al., “Effect of Antibody to HIV-1 Tat Protein on Viral replication in vitro and progression of HIV-1 disease in vivo,” J. of Acquired Immune Deficiency Syndromes and Human Retrovirology. Dec. 1, 1995, vol. 10, No. 4, pp. 408-416.
Rodman et al., “Human Immunodeficiency virus (HIV) Tat reactive antibodies present in normal HIV-negative sera and depleted in HIV-positive sera. Identification of the epitope,” J. of Experimental Medicine. May 1, 1992, vol. 175, No. 5, pp. 1247-1253.
Gringeri et al., Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients,Journal of Human Virology, 1:293-298 (1998).
Reiss et al., Contribution of antibody response to recombinant HIV-1 gene-encoded products nef, rev, tat, and protease in prediciting development of AIDS in HIV-1-infected individuals,Journal of Acquired Immune Deficiency Syndromes, 4:165-172 (1991).
Gibellini et al., Antibody to HIV-1 tat protein, a key molecule in HIV-1 pathogenesis. A brief review,Microbiologica, 24:197-205 (20010.
Zagury Daniel
Zagury Jean-Francois
Browdy and Neimark
Neovacs S.A.
Parkin Jeffrey S.
LandOfFree
Method for determining prognosis of HIV infected individuals does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for determining prognosis of HIV infected individuals, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for determining prognosis of HIV infected individuals will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3705030